logo
logo

Ambys Completes $47 Million Series A Extension To Advance Liver Cell Therapy Platform

Dec 21, 2021•over 3 years ago

Amount Raised

$47 Million

Round Type

series a

San FranciscoPlatformsAppsMobileSoftware

Description

Ambys Medicines, a company pioneering cell-based therapies for severe liver diseases, today announced it has completed a $47 million extension of its Series A financing. This brings the total Series A funding raised by Ambys to $107 million. Ambys is developing an entirely new approach to treating severe liver disease. The company's liver-cell production processes can produce, at scale, high-quality liver cells that function in vivo as normal healthy liver cells

Company Information

Company

Ambys Medicines

Location

San Francisco, California, United States

About

Ambys Medicines is focused on unlocking the full potential of hepatocyte transplantation and transforming the treatment of severe liver disease. Ambys' proprietary cell therapy platform potentially solves the supply constraints that have hindered progress, catalyzing the field and fundamentally transforming the approach to treating severe liver disease. Our lead program, AMI-918, and future engineered hepatocyte cell therapies are being developed across the spectrum of severe liver disease, including those of acquired and genetic origins. Visit us at ambys.com and follow us on Twitter, LinkedIn, and Instagram. ___________________________ 1 https://www.worldgastroenterology.org/publications/e-wgn/e-wgn-expert-point-of-view-articles-collection/global-burden-of-liver-disease-a-true-burden-on-health-sciences-and-economies 2 https://pubmed.ncbi.nlm.nih.gov/30266282/

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech